Navigation Links
Can Obama Plan Tackle Diabetes Crisis? Epinex Test Could Help
Date:3/10/2009

IRVINE, Calif., March 10 /PRNewswire/ -- Diabetes will be a huge burden on President Obama's $634 billion plan to expand and improve healthcare coverage. Epinex Diagnostics, a private biomedical company located in Irvine, California, has developed a new diabetes monitoring device that could relieve the burden of diabetes on our healthcare system.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090310/LA81722)

The Epinex G1A(TM) Rapid Diabetes Monitoring Index Test is a revolutionary monthly rapid test that uses glycated albumin to measure how much damage has been done to the body by excess sugar. The Epinex G1A(TM) test will be a significant asset to help keep costs down by introducing a monthly testing paradigm that has been proven effective. This test could allow doctors to take action sooner than current diabetes testing methods, reducing the severity and cost of diabetes and its complications, which include blindness, kidney failure and cardiac disease.

President Obama recently acknowledged, "crushing health care costs...drag down our economy, bankrupt our families, and represent the fastest-growing part of our budget." In an unprecedented commitment to a new, more effective approach to healthcare, the President has taken the challenge to keep raging costs under control by proposing the "largest investment ever" in preventive care.

Diabetes eats up an enormous chunk of our current healthcare resources. It has become the greatest healthcare crisis of our time, affecting one in three Americans. Last year alone, direct medical costs for diabetes totaled $116 billion, a 32% increase since 2002. Despite current efforts to manage the epidemic, the toll of diabetes continues to spiral out of control. However, pouring more resources into ineffective programs will only waste money.

Continuing to address the diabetes epidemic using methods of the past threatens to set up our health care system for failure. "The current treatment paradigm for diabetes doesn't work," explains Epinex CEO, Asad Zaidi. "With our current financial crisis, Epinex is working on a product that will help save our already over-burdened healthcare system billions of dollars, while helping diabetics manage their disease more effectively."

About Epinex Diagnostics, Inc.

Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests. Please find further information about the company and the G1A(TM) test at www.epinex.com.


'/>"/>
SOURCE Epinex Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
2. Environmental Tectonics Corporations BioMedical Divisions Hyperbaric Chambers Address U.S. President Obamas Initiative to Computerize Medical Records
3. Obama Advisor Joins Connecticut and International Scientists at New Haven Stem Cell Symposium
4. Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama
5. Cord Blood America Salutes President-Elect Obamas Promise to Lift Restrictions on Stem Cell Research
6. McCain and Obama on Bio-threat Detection and Pandemic Response: QualSec Weighs in
7. Old and new therapies combine to tackle atherosclerosis
8. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
9. New Report Tackles the Changing Landscape for Alzheimers Diagnostics and Treatments
10. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
11. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in an ... on RFD-TV. , With global population estimates nearing ten billion people by 2050, ... a growing nation. At the same time, many of our valuable resources are becoming ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
Breaking Biology News(10 mins):